Belite Bio targets completing stargardt NDA rolling submission in Q2 2026 while planning a 30-40 member U.S. launch team (NASDAQ:BLTE)
· seekingalpha.com
Belite Bio (BLTE) Q1 2026 earnings call: FDA rolling NDA for Stargardt, DRAGON updates, launch plans, burn and $799M cash—read key takeaways.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...